This week, FDA has approved an additional novel indication for canagliflozin (Invokana) for persons with type 2 diabetes and diabetes related kidney disease. Specifically, canagliflozin is now indicated to reduce worsening kidney function, risk of end stage renal disease, cardiovascular death and heart failure hospitalization in adults living with type 2 diabetes and kidney disease. Wow! Please click below to learn more.
Please share your thoughts and subscribe to receive my blogs.
#canagliflozin #novel #kidney #indication
Follow me on Twitter and Facebook @ReecesPiecesDi and Instagram ReecesPiecesDI.